We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Erasca Stock Surges 42% in a Week: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
ERAS shares surged 41.5% in a week following early phase I results from the ERAS-0015 AURORAS-1 study.
ERAS-0015 showed partial responses across RAS-mutant tumors, favorable safety, and linear PK.
ERAS also advanced ERAS-4001, with phase I dose escalation on track and initial KRAS-mutant data due in 2026.
Shares of Erasca (ERAS - Free Report) soared 41.5% in a week. The massive gain was observed after the company announced encouraging early clinical data from the phase I study of its investigational candidate, ERAS-0015, being developed for patients with RAS-mutant solid tumors.
Additionally, Erasca also announced updates from a separate early-stage study of another oncology candidate, ERAS-4001, along with its 2026-2027 milestones.
Erasca’s ERAS-0015 Study Initial Data in Detail
Per Erasca, ERAS-0015 is an oral, highly potent pan-RAS molecular glue that targets RAS signaling and has the potential to deliver a best-in-class therapeutic profile. The company reported that dose escalation in the ongoing phase I AURORAS-1 study of the candidate is progressing faster than originally anticipated, reflecting the significant unmet medical need in RAS-driven cancers as well as strong enthusiasm from investigators and patients. Enrollment momentum has supported rapid advancement through multiple dose levels.
Encouraging early efficacy signals have been observed across multiple tumor types and RAS mutations. At a low dose of 8 mg once daily, two confirmed partial responses and one unconfirmed partial response have been reported, with additional ongoing unconfirmed responses seen at higher dose levels.
In the past six months, shares of Erasca have skyrocketed 541.6% compared with the industry’s 23.2% growth.
Image Source: Zacks Investment Research
ERAS-0015 has also demonstrated a favorable safety and tolerability profile to date. No dose-limiting toxicities have been observed, and adverse events have been predominantly low grade across all evaluated dose levels, supporting continued dose escalation and expansion.
Pharmacokinetic data indicate a well-behaved, linear profile across all tested doses, with no evidence of an exposure plateau as of the data cutoff date of Jan. 7, 2026. This supports predictable dosing and provides flexibility for future monotherapy and combination strategies.
Looking ahead, initial phase I ERAS-0015 monotherapy data in patients with RAS-mutant solid tumors are expected in the first half of 2026. Erasca plans to initiate monotherapy expansion cohorts and combination dose-escalation cohorts in the AURORAS-1 study in late 2026, with expansion and combination data anticipated in 2027.
Update on Erasca’s Other Pipeline Candidate
Apart from ERAS-0015, Erasca’s clinical-stage pipeline comprises another candidate currently undergoing phase I development for patients with KRAS-mutant solid tumors. Per the company, ERAS-4001 is an oral, highly potent and highly selective pan-KRAS inhibitor with the potential to deliver both first-in-class and best-in-class performance.
In the same press release, Erasca reported that dose escalation in the ongoing phase I BOREALIS-1 study of ERAS-4001 for KRAS-mutant solid tumors is progressing as planned, supporting the program’s development timeline.
Initial phase I ERAS-4001 monotherapy data in patients with KRAS-mutant solid tumors are expected in the second half of 2026, covering safety, tolerability, pharmacokinetics and early efficacy. The company also plans to initiate monotherapy expansion cohorts and combination dose-escalation cohorts in the BOREALIS-1 study in 2027.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have decreased from 67 cents to 65 cents. Shares of FOLD have surged 127.6% over the past six months.
Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark on the other three occasions, delivering an average negative surprise of 20.21%.
Over the past 60 days, 2026 EPS estimates for Alkermes have increased from $1.54 to $1.80. Shares of ALKS have gained 6.3% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, missing on the remaining occasion, with the average surprise being 4.58%.
Over the past 60 days, estimates for Krystal Biotech’s EPS for 2026 have risen to $8.49 from $8.34. KRYS stock has rallied 87.8% over the past six months.
Krystal Biotech’s earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 40.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Erasca Stock Surges 42% in a Week: Here's What You Should Know
Key Takeaways
Shares of Erasca (ERAS - Free Report) soared 41.5% in a week. The massive gain was observed after the company announced encouraging early clinical data from the phase I study of its investigational candidate, ERAS-0015, being developed for patients with RAS-mutant solid tumors.
Additionally, Erasca also announced updates from a separate early-stage study of another oncology candidate, ERAS-4001, along with its 2026-2027 milestones.
Erasca’s ERAS-0015 Study Initial Data in Detail
Per Erasca, ERAS-0015 is an oral, highly potent pan-RAS molecular glue that targets RAS signaling and has the potential to deliver a best-in-class therapeutic profile. The company reported that dose escalation in the ongoing phase I AURORAS-1 study of the candidate is progressing faster than originally anticipated, reflecting the significant unmet medical need in RAS-driven cancers as well as strong enthusiasm from investigators and patients. Enrollment momentum has supported rapid advancement through multiple dose levels.
Encouraging early efficacy signals have been observed across multiple tumor types and RAS mutations. At a low dose of 8 mg once daily, two confirmed partial responses and one unconfirmed partial response have been reported, with additional ongoing unconfirmed responses seen at higher dose levels.
In the past six months, shares of Erasca have skyrocketed 541.6% compared with the industry’s 23.2% growth.
Image Source: Zacks Investment Research
ERAS-0015 has also demonstrated a favorable safety and tolerability profile to date. No dose-limiting toxicities have been observed, and adverse events have been predominantly low grade across all evaluated dose levels, supporting continued dose escalation and expansion.
Pharmacokinetic data indicate a well-behaved, linear profile across all tested doses, with no evidence of an exposure plateau as of the data cutoff date of Jan. 7, 2026. This supports predictable dosing and provides flexibility for future monotherapy and combination strategies.
Looking ahead, initial phase I ERAS-0015 monotherapy data in patients with RAS-mutant solid tumors are expected in the first half of 2026. Erasca plans to initiate monotherapy expansion cohorts and combination dose-escalation cohorts in the AURORAS-1 study in late 2026, with expansion and combination data anticipated in 2027.
Update on Erasca’s Other Pipeline Candidate
Apart from ERAS-0015, Erasca’s clinical-stage pipeline comprises another candidate currently undergoing phase I development for patients with KRAS-mutant solid tumors. Per the company, ERAS-4001 is an oral, highly potent and highly selective pan-KRAS inhibitor with the potential to deliver both first-in-class and best-in-class performance.
In the same press release, Erasca reported that dose escalation in the ongoing phase I BOREALIS-1 study of ERAS-4001 for KRAS-mutant solid tumors is progressing as planned, supporting the program’s development timeline.
Initial phase I ERAS-4001 monotherapy data in patients with KRAS-mutant solid tumors are expected in the second half of 2026, covering safety, tolerability, pharmacokinetics and early efficacy. The company also plans to initiate monotherapy expansion cohorts and combination dose-escalation cohorts in the BOREALIS-1 study in 2027.
Erasca, Inc. Price and Consensus
Erasca, Inc. price-consensus-chart | Erasca, Inc. Quote
ERAS’ Zacks Rank and Stocks to Consider
Erasca currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amicus Therapeutics (FOLD - Free Report) , Alkermes (ALKS - Free Report) and Krystal Biotech (KRYS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have decreased from 67 cents to 65 cents. Shares of FOLD have surged 127.6% over the past six months.
Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark on the other three occasions, delivering an average negative surprise of 20.21%.
Over the past 60 days, 2026 EPS estimates for Alkermes have increased from $1.54 to $1.80. Shares of ALKS have gained 6.3% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, missing on the remaining occasion, with the average surprise being 4.58%.
Over the past 60 days, estimates for Krystal Biotech’s EPS for 2026 have risen to $8.49 from $8.34. KRYS stock has rallied 87.8% over the past six months.
Krystal Biotech’s earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 40.43%.